Company profile
INMUNE BIO, INC.
NASDAQ:INMBBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| PEGIPANERMIN | phase2_3 | — | 5 | completed, terminated, withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03943264 | phase1 | completed | 2019-11-20 | 2021-06-30 | Inmune Bio, Inc. | A Biomarker-directed Study of XPro1595 in Patients With Alzheimer's |
| NCT05933070 | phase1 | terminated | 2020-06-15 | 2024-03-28 | Inmune Bio, Inc. | A Phase I Open-Label Dose Escalation Study of Intravenous INKmune In Patients With MDS or AML |
| NCT05318976 | phase2 | completed | 2022-02-28 | 2025-05-12 | Inmune Bio, Inc. | A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation |
| NCT05522387 | phase2 | terminated | 2023-02-21 | 2024-06-05 | Inmune Bio, Inc. | An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease |
| NCT04370236 | phase2_3 | terminated | 2020-10-21 | 2021-10-13 | Inmune Bio, Inc. | INB03 for the Treatment of Pulmonary Complications From COVID-19 |
FDA applications (0)
No records yet.